Study wrapper · #667
[Effect of a combined physiotherapeutic approach on changes in functional parameters after endovitreal surgery of rhegmatogenous retinal detachment with a favorable anatomical outcome].
Editor's note
This is a human clinical study in which Semax appears as an active treatment component after retinal-detachment surgery — an unusual, ophthalmology-adjacent use of a tracked peptide. In 42 patients with favorable anatomical outcomes after vitrectomy, one group (n=23) received combined physiotherapy including endonasal electrophoresis of 1% Semax solution plus helium-oxygen inhalation from day 5, while the other (n=19) received 0.1% Semax nasal drops. Over 12 months, researchers reported that the combined-physiotherapy group had better recovery of best-corrected visual acuity and microperimetry parameters by month 6 than the drops group. For Semax, this is peripheral to its usual neuroprotective/nootropic framing and does not isolate Semax's contribution, since both arms received it within different regimens. The design is small, appears non-randomized/retrospectively grouped, and compares delivery-plus-adjuncts rather than Semax versus no Semax. Weigh it as weak, hypothesis-level human data; findings are specific to this rehabilitation protocol.
Plain-language abstract
This study followed 42 people recovering from surgery for a detached retina, where the surgery itself had gone well. It tested whether adding a combination of physical therapies helped visual recovery. One group of 23 patients received, starting five days after surgery, breathing of a helium-oxygen mixture plus a nasal electrical-delivery treatment ('electrophoresis') of the peptide Semax. The other group of 19 received Semax as nasal drops instead. Over 12 months, the group getting the combined therapy had better recovery of corrected vision and of a detailed retinal-sensitivity measure by the six-month mark than the drops group. The authors conclude the combination is a promising rehabilitation approach. Both groups actually received Semax, just delivered differently and alongside other treatments, so the study does not show what Semax alone contributed. It was small and did not appear to randomly assign patients. It is a weak, early human signal about a rehabilitation protocol that happens to include Semax, not evidence about the peptide on its own.